Navigation Links
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Date:6/11/2009

SAN FRANCISCO, June 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer's disease.

The international, double-blind, placebo-controlled, pivotal Phase 3 study enrolled 598 patients, exceeding the enrollment target of 525 patients. More than 40 percent of the patients enrolled were in the United States. The six-month study is evaluating the effect of dimebon on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinician's Interview-Based Impression of Change plus caregiver interview (CIBIC-plus) -- the two endpoints have historically been accepted by the U.S. Food and Drug Administration (FDA) to support registration of currently approved drugs for mild-to-moderate Alzheimer's disease.

"Completion of patient enrollment in this second pivotal trial moves us closer to our goal of submitting a marketing application to the FDA and bringing dimebon to market for the many Alzheimer's patients suffering from this devastating disease," said Lynn Seely, M.D., chief medical officer of Medivation. "We are gratified by the strong interest in this trial as indicated by our exceeding the enrollment goal. Together with our partner Pfizer, we are executing a comprehensive clinical plan to support an NDA filing, currently targeted for 2011, with a broad and differentiated label for dimebon in Alzheimer's disease. We are also conducting a Phase 3 safety study, which will provide us and Pfizer the opportunity to seek marketing approval earlier if results of the CONNECTION study confirm our previously completed first pivotal study, which was published in the Lancet last year."


'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Pricing of Public Offering
2. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
3. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
4. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
5. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
8. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
10. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
11. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 Rainbow Scientific, ... research products, recently opened an online store to ... culture product lines developed and manufactured by Biological ... store include Biological Industries’ Nutristem® serum-free, xeno-free reagents ... embryonic stem cell (hESC) culture. , The ...
(Date:9/30/2014)... Whitehouse Laboratories is pleased to ... Parenteral Drug Association (PDA) to host a unique ... closure integrity testing. This lecture/laboratory course will examine the ... detailed in the recently proposed revision to USP 1207 ... will span container closure integrity testing (leak testing) critical ...
(Date:9/29/2014)... 30, 2014 Each year in ... require medical attention. In the military, burn injury ... to battlefield medical care. More than 800 service ... Burn wounds heal slowly, remain inflamed and often ... physically debilitating and functionally damaging. While developments in ...
(Date:9/29/2014)... BEACH, Va. , Sept. 29, 2014 /PRNewswire-USNewswire/ ... from the fields of cartilage repair, regeneration, allograft ... attendees from around the world gathered to discuss ... LifeNet Health Institute of Regenerative Medicine symposium, ... Direction . Topics included Orthopedic Biosurgery, Minced Juvenile ...
Breaking Biology Technology:Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Faster Healing with Fewer Scars 2World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... Organization Exceeds Expectations, MEMPHIS, Tenn., Nov. ... exclusively focused on oncology, announced today that ... as the company continues,to experience banner growth. ... to consistently exceed client expectations, and we ...
... N.J., Nov. 10 Aton Pharma, Inc., ... a recent,survey of ophthalmologists regarding issues in ... dry eye. Aton provides the dry eye ... sustained release prescription insert that helps to ...
... 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology company focused ... in China,today announced that it has filed with ... approval of NuLeusin for the treatment of late,stage ... expected to,be the only treatment of this kind ...
Cached Biology Technology:ACORN CRO Continues Growth in Strong Third Quarter 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 3Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 4Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 53SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4
(Date:9/29/2014)... research team says recently identified radiation detection properties of ... doors for homeland security and medical advances. , In ... issue of Optics Letters , UT Arlington Physics ... method to fabricate transparent nanoscintillators by heating nanoparticles composed ... is formed. A scintillator refers to a material ...
(Date:9/29/2014)... has presented Dr. Cristin Samper, president and CEO ... Order of San Carlos. , The Order of ... military officers who have made outstanding contributions to ... relations. , An international authority on conservation biology ... the Colombian Residence in New York to receive ...
(Date:9/29/2014)... annual Advocacy Awards will ... advancing medical progress to improve the health and ... take place on Wednesday, March 11, 2015, at ... , The 2015 Advocacy Award winners are ABC,s ... founder of the Milken Institute and FasterCures; Dr. ...
Breaking Biology News(10 mins):UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 4
... warming despite emitting small amounts of an important greenhouse gas, ... of Edinburgh suggests that plant leaves account for less than ... is considered to be about 25 times more effective than ... a previous scientific study which had suggested that plants were ...
... WASHINGTON, April 29, 2010 The American Chemical ... has awarded its 2010 research grant to Scottish ... strides in expanding green chemistry and engineering practices ... the one-year $150,000-grant to further his study of ...
... Thomas Miller , an internationally recognized expert at ... and genetics, has been chosen by the U.S. Department ... Fellowship . Miller is one of only ten ... applicants undergo a rigorous selection process, are highly accomplished ...
Cached Biology News:ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist 2US Department of State names UCR entomologist a Jefferson Science Fellow 2US Department of State names UCR entomologist a Jefferson Science Fellow 3